

# Vlado Perkovic

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4434428/publications.pdf>

Version: 2024-02-01

268  
papers

37,565  
citations

4370

86  
h-index

3173

186  
g-index

291  
all docs

291  
docs citations

291  
times ranked

28319  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 644-657.  | 13.9 | 5,629     |
| 2  | Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019, 380, 2295-2306.   | 13.9 | 3,760     |
| 3  | Worldwide access to treatment for end-stage kidney disease: a systematic review. <i>Lancet, The</i> , 2015, 385, 1975-1982.   | 6.3  | 1,522     |
| 4  | Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 69.     | 3.8  | 830       |
| 5  | Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. <i>Lancet, The</i> , 2016, 387, 435-443.  | 6.3  | 792       |
| 6  | Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. <i>Lancet, The</i> , 2010, 375, 1875-1884.   | 6.3  | 788       |
| 7  | Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1813-1821.                                | 3.0  | 787       |
| 8  | Blood Pressure Lowering in Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 603.   | 3.8  | 673       |
| 9  | A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. <i>Lancet, The</i> , 2016, 388, 2665-2712. | 6.3  | 670       |
| 10 | Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet, The</i> , 2017, 390, 1888-1917.  | 6.3  | 662       |
| 11 | SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology, the</i> , 2019, 7, 845-854.                      | 5.5  | 595       |
| 12 | Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2014, 371, 1392-1406.   | 13.9 | 520       |
| 13 | Chronic kidney disease. <i>Lancet, The</i> , 2021, 398, 786-802.  | 6.3  | 478       |
| 14 | Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. <i>Lancet Diabetes and Endocrinology, the</i> , 2018, 6, 691-704.                                    | 5.5  | 460       |
| 15 | Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 393, 1937-1947.                     | 6.3  | 408       |
| 16 | Coffee, Decaffeinated Coffee, and Tea Consumption in Relation to Incident Type 2 Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2009, 169, 2053.   | 4.3  | 407       |
| 17 | Is Low Birth Weight an Antecedent of CKD in Later Life? A Systematic Review of Observational Studies. <i>American Journal of Kidney Diseases</i> , 2009, 54, 248-261.   | 2.1  | 406       |
| 18 | Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. <i>Circulation</i> , 2018, 137, 323-334.   | 1.6  | 393       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis. PLoS Medicine, 2012, 9, e1001293.   | 3.9  | 389       |
| 20 | Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet, The, 2009, 373, 1009-1015.   | 6.3  | 384       |
| 21 | Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology, the, 2016, 4, 411-419.  | 5.5  | 384       |
| 22 | Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ: British Medical Journal, 2008, 336, 645-651.  | 2.4  | 382       |
| 23 | Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. JAMA - Journal of the American Medical Association, 2017, 318, 432.  | 3.8  | 376       |
| 24 | Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus. Circulation, 2018, 138, 458-468.   | 1.6  | 370       |
| 25 | Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. American Journal of Kidney Diseases, 2020, 75, 84-104. | 2.1  | 311       |
| 26 | Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease. Annals of Internal Medicine, 2010, 153, 23.   | 2.0  | 297       |
| 27 | Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)â€”A randomized placebo-controlled trial. American Heart Journal, 2013, 166, 217-223.e11.  | 1.2  | 290       |
| 28 | Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea. JAMA - Journal of the American Medical Association, 2017, 318, 156.  | 3.8  | 287       |
| 29 | Effects of Allopurinol on the Progression of Chronic Kidney Disease. New England Journal of Medicine, 2020, 382, 2504-2513.   | 13.9 | 281       |
| 30 | Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. Journal of the American Society of Nephrology: JASN, 2017, 28, 368-375.  | 3.0  | 280       |
| 31 | The Burden of Blood Pressure-Related Disease. Hypertension, 2007, 50, 991-997.  | 1.3  | 277       |
| 32 | Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. American Journal of Kidney Diseases, 2016, 67, 728-741.  | 2.1  | 277       |
| 33 | Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International, 2013, 83, 517-523.   | 2.6  | 256       |
| 34 | Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction. Diabetes Care, 2013, 36, 3460-3468.   | 4.3  | 253       |
| 35 | Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2009, 20, 883-892.  | 3.0  | 245       |
| 36 | Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. Cmaj, 2013, 185, 949-957.   | 0.9  | 232       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 2068-2074.   | 4.3 | 230       |
| 38 | Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. <i>European Heart Journal</i> , 2008, 29, 2669-2680.   | 1.0 | 225       |
| 39 | Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 128-139.                                   | 5.5 | 223       |
| 40 | The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1083-1093.  | 3.0 | 222       |
| 41 | Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. <i>Circulation</i> , 2018, 138, 1537-1550.  | 1.6 | 200       |
| 42 | Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 115-127.                              | 5.5 | 199       |
| 43 | Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 403-411.                                     | 4.3 | 196       |
| 44 | Long-Term Cancer Risk of Immunosuppressive Regimens after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 852-858.   | 3.0 | 194       |
| 45 | The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017, 46, 462-472.                     | 1.4 | 194       |
| 46 | Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 406-413.   | 0.4 | 191       |
| 47 | Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1237-1250. | 2.2 | 190       |
| 48 | The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis. <i>PLoS Medicine</i> , 2008, 5, e207.  | 3.9 | 189       |
| 49 | The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. <i>Journal of Hypertension</i> , 2011, 29, 4-16. | 0.3 | 189       |
| 50 | Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. <i>Diabetes Care</i> , 2016, 39, 694-700.  | 4.3 | 184       |
| 51 | Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2012, 156, 445.  | 2.0 | 179       |
| 52 | Omega 3 Fatty Acids and Cardiovascular Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 808-818.  | 0.9 | 175       |
| 53 | Aspirin Is Beneficial in Hypertensive Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2010, 56, 956-965.   | 1.2 | 171       |
| 54 | Corticosteroid Therapy in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1108-1116.  | 3.0 | 163       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2013, 34, 1807-1817.   | 1.0  | 156       |
| 56 | Effects of Beta-Adrenergic Antagonists in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1152-1161.  | 1.2  | 148       |
| 57 | Effects of Fibrates in Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2061-2071.   | 1.2  | 148       |
| 58 | Effects of the Mediterranean Diet on Cardiovascular Outcomes—A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0159252.  | 1.1  | 145       |
| 59 | HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. <i>The Cochrane Library</i> , 2014, , CD007784.  | 1.5  | 141       |
| 60 | Rationale, design and baseline characteristics of the CANagliptin cardioVascular Assessment Study—Renal (<scp>CANVAS</scp>): A randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 387-393.            | 2.2  | 139       |
| 61 | Redefining Blood-Pressure Targets — SPRINT Starts the Marathon. <i>New England Journal of Medicine</i> , 2015, 373, 2175-2178.   | 13.9 | 134       |
| 62 | Chronic kidney disease and the global NCDs agenda. <i>BMJ Global Health</i> , 2017, 2, e000380.  | 2.0  | 132       |
| 63 | Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. <i>BMJ: British Medical Journal</i> , 2019, 367, l5873.  | 2.4  | 131       |
| 64 | Proteinuria and Stroke: A Meta-analysis of Cohort Studies. <i>American Journal of Kidney Diseases</i> , 2009, 53, 417-425.   | 2.1  | 128       |
| 65 | Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. <i>Circulation</i> , 2019, 139, 351-361.  | 1.6  | 126       |
| 66 | The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. <i>BMJ, The</i> , 2015, 350, h246-h246.                               | 3.0  | 125       |
| 67 | Isolated Low Levels of High-Density Lipoprotein Cholesterol Are Associated With an Increased Risk of Coronary Heart Disease. <i>Circulation</i> , 2011, 124, 2056-2064.  | 1.6  | 122       |
| 68 | Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized <scp>MARLINA</scp>—<scp>T2D</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1610-1619. | 2.2  | 119       |
| 69 | Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 2325-2335.  | 13.9 | 112       |
| 70 | Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes. <i>American Journal of Kidney Diseases</i> , 2012, 60, 770-778.  | 2.1  | 110       |
| 71 | Parathyroid Hormone Has a Prosclerotic Effect on Vascular Smooth Muscle Cells. <i>Kidney and Blood Pressure Research</i> , 2003, 26, 27-33.  | 0.9  | 109       |
| 72 | Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2019, 171, 181.   | 2.0  | 108       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 2313-2324.   | 13.9 | 108       |
| 74 | Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 64-74.   | 1.4  | 106       |
| 75 | Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1128-1139.   | 3.0  | 106       |
| 76 | Effect of Hemodiafiltration or Hemofiltration Compared With Hemodialysis on Mortality and Cardiovascular Disease in Chronic Kidney Failure: A Systematic Review and Meta-analysis of Randomized Trials. <i>American Journal of Kidney Diseases</i> , 2014, 63, 968-978.                                 | 2.1  | 105       |
| 77 | Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1888.  | 3.8  | 103       |
| 78 | Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2766-2772.  | 3.0  | 97        |
| 79 | Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. <i>Circulation</i> , 2022, 145, 1460-1470.  | 1.6  | 97        |
| 80 | Accelerated Progression of Calcific Aortic Stenosis in Dialysis Patients. <i>Nephron Clinical Practice</i> , 2003, 94, c40-c45.   | 2.3  | 95        |
| 81 | Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2827-2847. | 0.4  | 94        |
| 82 | Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. <i>Diabetologia</i> , 2019, 62, 926-938.  | 2.9  | 94        |
| 83 | Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2229-2242.  | 3.0  | 93        |
| 84 | Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2020, 8, 57-66.   | 1.9  | 93        |
| 85 | Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. <i>American Journal of Kidney Diseases</i> , 2015, 66, 441-449.  | 2.1  | 91        |
| 86 | Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 926-935.  | 2.2  | 89        |
| 87 | Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. <i>Circulation</i> , 2022, 145, 575-585.  | 1.6  | 88        |
| 88 | Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. <i>European Heart Journal</i> , 2010, 31, 2888-2896.  | 1.0  | 85        |
| 89 | HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. , 2009, , CD007784.   |      | 84        |
| 90 | The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. <i>BMJ, The</i> , 2012, 344, e3533-e3533.   | 3.0  | 83        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Antiplatelet Therapy to Prevent Hemodialysis Vascular Access Failure: Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2013, 61, 112-122.   | 2.1 | 81        |
| 92  | Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. European Heart Journal, 2021, 42, 4891-4901.   | 1.0 | 80        |
| 93  | Preoperative Estimates of Glomerular Filtration Rate as Predictors of Outcome after Surgery. Anesthesiology, 2013, 118, 809-824.   | 1.3 | 78        |
| 94  | Survival of elderly dialysis patients is predicted by both patient and practice characteristics. Nephrology Dialysis Transplantation, 2012, 27, 3581-3587.   | 0.4 | 75        |
| 95  | Intensities of Renal Replacement Therapy in Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 956-963.  | 2.2 | 73        |
| 96  | Research Priorities in CKD: Report of a National Workshop Conducted in Australia. American Journal of Kidney Diseases, 2015, 66, 212-222.  | 2.1 | 73        |
| 97  | Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes and Endocrinology, 2020, 8, 903-914.   | 5.5 | 73        |
| 98  | Prevalence of chronic kidney disease in Asia: a systematic review and analysis. BMJ Global Health, 2022, 7, e007525.   | 2.0 | 73        |
| 99  | Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review. Diabetes Research and Clinical Practice, 2018, 140, 118-128.   | 1.1 | 71        |
| 100 | Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabetes and Vascular Disease Research, 2012, 9, 117-123.  | 0.9 | 70        |
| 101 | Rationale, design, and baseline characteristics of the Cardiovascular safety and Renal Microvascular outcome study with LINagliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovascular Diabetology, 2018, 17, 39. | 2.7 | 70        |
| 102 | Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney International, 2020, 98, 769-777.  | 2.6 | 69        |
| 103 | Antihypertensive agents for preventing diabetic kidney disease. The Cochrane Library, 2012, 12, CD004136.  | 1.5 | 68        |
| 104 | HMG CoA reductase inhibitors (statins) for dialysis patients. , 2009, , CD004289.  |     | 65        |
| 105 | The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care, 2014, 37, 295-303.  | 4.3 | 65        |
| 106 | International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney International, 2020, 98, 849-859.  | 2.6 | 65        |
| 107 | Relationship Between Levels of Advanced Glycation End Products and Their Soluble Receptor and Adverse Outcomes in Adults With Type 2 Diabetes. Diabetes Care, 2015, 38, 1891-1897.   | 4.3 | 62        |
| 108 | A Trial of Extending Hemodialysis Hours and Quality of Life. Journal of the American Society of Nephrology: JASN, 2017, 28, 1898-1911.   | 3.0 | 62        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Antiplatelet agents for chronic kidney disease. , 2013, , CD008834.  |     | 61        |
| 110 | Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes, Obesity and Metabolism, 2018, 20, 1369-1376.         | 2.2 | 60        |
| 111 | Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1027-1036.                              | 2.6 | 60        |
| 112 | Resting Heart Rate and the Risk of Microvascular Complications in Patients With Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2012, 1, e002832.   | 1.6 | 59        |
| 113 | HMG CoA reductase inhibitors (statins) for kidney transplant recipients. The Cochrane Library, 2015, 2015, CD005019.   | 1.5 | 58        |
| 114 | Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia, 2019, 62, 1854-1867.   | 2.9 | 58        |
| 115 | HMG CoA reductase inhibitors (statins) for dialysis patients. The Cochrane Library, 2014, 2014, CD004289.  | 1.5 | 54        |
| 116 | Tripterygium Preparations for the Treatment of CKD: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2013, 62, 515-530.   | 2.1 | 53        |
| 117 | Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home. American Journal of Kidney Diseases, 2013, 61, 247-253.   | 2.1 | 52        |
| 118 | Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke, 2019, 50, 396-404.   | 1.0 | 51        |
| 119 | Blood Pressure Is a Major Risk Factor for Renal Death. Hypertension, 2009, 54, 509-515.  | 1.3 | 50        |
| 120 | Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension, 2010, 28, 1141-1149.  | 0.3 | 50        |
| 121 | Renal effects of canagliflozin in type 2 diabetes mellitus. Current Medical Research and Opinion, 2015, 31, 2219-2231.   | 0.9 | 49        |
| 122 | Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. The Cochrane Library, 2018, 9, CD011798.   | 1.5 | 48        |
| 123 | Circulating bone morphogenetic protein-7 and transforming growth factor- $\beta$ 1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney International, 2013, 83, 278-284. | 2.6 | 47        |
| 124 | Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nature Reviews Nephrology, 2011, 7, 295-300.  | 4.1 | 46        |
| 125 | Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. Diabetes Care, 2018, 41, 163-170.   | 4.3 | 46        |
| 126 | Socioeconomic Disadvantage and Kidney Disease in the United States, Australia, and Thailand. American Journal of Public Health, 2008, 98, 1306-1313.   | 1.5 | 45        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. <i>Diabetologia</i> , 2021, 64, 2147-2158.   | 2.9 | 45        |
| 128 | The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. <i>Diabetologia</i> , 2019, 62, 1988-1997.  | 2.9 | 44        |
| 129 | Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 1803-1812.  | 4.3 | 44        |
| 130 | Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1396-1402.   | 0.4 | 42        |
| 131 | Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. <i>Nephrology</i> , 2012, 17, 433-444.  | 0.7 | 42        |
| 132 | Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2289-2302.  | 3.0 | 39        |
| 133 | Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINAâ€“T2D<sup>â„“</sup> trial. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 455-462. | 0.9 | 39        |
| 134 | Warfarin Initiation, Atrial Fibrillation, and Kidney Function:â€“Comparative Effectiveness and Safety ofâ€“Warfarinâ€“inâ€“Olderâ€“Adultsâ€“With Newly Diagnosed Atrialâ€“Fibrillation. <i>American Journal of Kidney Diseases</i> , 2017, 69, 734-743.                                    | 2.1 | 38        |
| 135 | The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. <i>Lancet Rheumatology</i> , The, 2019, 1, e220-e228.  | 2.2 | 38        |
| 136 | Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 384-395.  | 2.2 | 37        |
| 137 | Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. <i>Diabetes Therapy</i> , 2015, 6, 289-302.  | 1.2 | 36        |
| 138 | The $\beta$ -Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 902-911.   | 2.1 | 36        |
| 139 | Cyclosporine Withdrawal Improves Long-Term Graft Survival in Renal Transplantation. <i>Transplantation</i> , 2009, 87, 1877-1883.  | 0.5 | 35        |
| 140 | The Authors Reply. <i>Kidney International</i> , 2013, 84, 622.  | 2.6 | 34        |
| 141 | Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2058-2066.   | 2.2 | 33        |
| 142 | Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1568-1574.   | 2.2 | 32        |
| 143 | Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study. <i>PLoS ONE</i> , 2019, 14, e0213192.  | 1.1 | 32        |
| 144 | The risk of cancer in people with diabetes and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3337-3344.   | 0.4 | 31        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 145 | The effect of canagliflozin on amputation risk in the <sc>CANVAS</sc> program and the <sc>CRENDENCE</sc> trial. Diabetes, Obesity and Metabolism, 2020, 22, 1753-1766.  | 2.2  | 31        |
| 146 | Treatment of renovascular disease with percutaneous stent insertion: Long-term outcomes. Journal of Medical Imaging and Radiation Oncology, 2001, 45, 438-443.  | 0.6  | 30        |
| 147 | Trials in Kidney Disease â€” Time to EVOLVE. New England Journal of Medicine, 2012, 367, 2541-2542.   | 13.9 | 30        |
| 148 | Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CRENDENCE trial. American Heart Journal, 2021, 233, 141-148.                 | 1.2  | 30        |
| 149 | Effects of salt substitute on pulse wave analysis among individuals at high cardiovascular risk in rural China: a randomized controlled trial. Hypertension Research, 2009, 32, 282-288.  | 1.5  | 29        |
| 150 | A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial. American Journal of Kidney Diseases, 2015, 65, 49-57. | 2.1  | 29        |
| 151 | Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. European Journal of Preventive Cardiology, 2016, 23, 758-768.  | 0.8  | 29        |
| 152 | Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 862-872.  | 2.2  | 29        |
| 153 | Prospective evaluation of aortic stenosis in end-stage kidney disease: a more fulminant process?. Nephrology Dialysis Transplantation, 2011, 26, 1651-1655.   | 0.4  | 28        |
| 154 | Baseline characteristics and enrichment results from the <sc>SONAR</sc> trial. Diabetes, Obesity and Metabolism, 2018, 20, 1829-1835.   | 2.2  | 28        |
| 155 | Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients. JAMA Internal Medicine, 2022, 182, 592.   | 2.6  | 28        |
| 156 | Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. Journal of Hypertension, 2009, 27, 2321-2331.   | 0.3  | 27        |
| 157 | HMG CoA reductase inhibitors (statins) for kidney transplant recipients. , 2009, , CD005019.  |      | 26        |
| 158 | Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. Nephrology Dialysis Transplantation, 2013, 28, 2875-2888.                     | 0.4  | 26        |
| 159 | Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. Therapeutic Advances in Chronic Disease, 2011, 2, 265-278.  | 1.1  | 25        |
| 160 | Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey. BMJ Open, 2021, 11, e047245.   | 0.8  | 25        |
| 161 | Relationship between Serum Uric Acid Levels and Chronic Kidney Disease in a Japanese Cohort with Normal or Mildly Reduced Kidney Function. PLoS ONE, 2015, 10, e0137449.  | 1.1  | 24        |
| 162 | Hemodialysis Use and Practice Patterns: An International Survey Study. American Journal of Kidney Diseases, 2021, 77, 326-335.e1.   | 2.1  | 24        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Co-payments for health care: what is their real cost?. Australian Health Review, 2015, 39, 33.   | 0.5 | 23        |
| 164 | Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. American Journal of Kidney Diseases, 2022, 79, 244-256.e1.  | 2.1 | 23        |
| 165 | Dose of haemodialysis. Nephrology, 2005, 10, S61-S63.  | 0.7 | 22        |
| 166 | Interventions for lowering plasma homocysteine levels in dialysis patients. The Cochrane Library, 2016, 2016, CD004683.  | 1.5 | 21        |
| 167 | Lowering cholesterol in chronic kidney disease: is it safe and effective?. European Heart Journal, 2015, 36, 2988-2995.  | 1.0 | 20        |
| 168 | Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. The Cochrane Library, 2017, 2, CD009966.   | 1.5 | 20        |
| 169 | Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME <sup>®</sup> trial. Nephrology Dialysis Transplantation, 2020, 35, 2103-2111.  | 0.4 | 20        |
| 170 | Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 1072-1083. | 2.2 | 20        |
| 171 | The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes, Obesity and Metabolism, 2017, 19, 749-753.  | 2.2 | 19        |
| 172 | Action plan for optimizing the design of clinical trials in chronic kidney disease. Kidney International Supplements, 2017, 7, 138-144.  | 4.6 | 19        |
| 173 | New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. Diabetes, Obesity and Metabolism, 2018, 20, 14-18.   | 2.2 | 19        |
| 174 | Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 251-259.                                       | 2.2 | 19        |
| 175 | ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension, 2006, 24, S22-S28.   | 0.3 | 18        |
| 176 | Global Randomized Trials: The Promise of India and China. Journal of Bone and Joint Surgery - Series A, 2012, 94, 92-96.   | 1.4 | 18        |
| 177 | Design and participant baseline characteristics of a <scp>C</scp>linical <scp>T</scp>rial of <scp>Intensive D</scp>ialysis <sup>™</sup> : The <scp>ACTIVE D</scp>ialysis <scp>S</scp>tudy. Nephrology, 2015, 20, 257-265.        | 0.7 | 18        |
| 178 | Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. CKJ: Clinical Kidney Journal, 2021, 14, 1396-1402.  | 1.4 | 18        |
| 179 | Intensive Glycemic Control and Renal Outcome. Contributions To Nephrology, 2011, 170, 196-208.   | 1.1 | 17        |
| 180 | Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network. Kidney International, 2014, 85, 23-30.   | 2.6 | 17        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial. <i>Diabetology International</i> , 2020, 11, 129-141. | 0.7 | 17        |
| 182 | Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e021661.   | 1.6 | 16        |
| 183 | Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2446-2456.  | 3.0 | 15        |
| 184 | The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2021, 52, 827-836.  | 1.4 | 15        |
| 185 | Diuretics: A modern day treatment option? (Review Article). <i>Nephrology</i> , 2006, 11, 419-427.   | 0.7 | 14        |
| 186 | Industry-Sponsored Clinical Trials in Emerging Markets. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 907.  | 3.8 | 14        |
| 187 | Closing the gap between evidence and practice in chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 114-121.   | 4.6 | 14        |
| 188 | Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 530-539.   | 2.2 | 14        |
| 189 | Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology. <i>Kidney International Supplements</i> , 2018, 8, 82-89.  | 4.6 | 13        |
| 190 | Varying Association of Extended Hours Dialysis with Quality of Life. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1751-1762.   | 2.2 | 13        |
| 191 | Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial. <i>Cardiovascular Research</i> , 2022, 118, 1103-1114.  | 1.8 | 13        |
| 192 | mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 242-244.  | 0.4 | 12        |
| 193 | Cardiovascular disease in patients with chronic kidney disease. <i>Nephrology</i> , 2014, 19, 3-10.  | 0.7 | 12        |
| 194 | Quality of life in caregivers compared with dialysis recipients: The CoACTIVE sub-study of the ACTIVE dialysis trial. <i>Nephrology</i> , 2019, 24, 1056-1063.   | 0.7 | 12        |
| 195 | The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 763-773.  | 2.2 | 12        |
| 196 | Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. <i>Nephrology</i> , 2017, 22, 548-554.                                    | 0.7 | 11        |
| 197 | Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 561-568.       | 2.2 | 10        |
| 198 | Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1365-1375.  | 2.2 | 10        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 199 | Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1927-1938.                                   | 2.2 | 10        |
| 200 | Hematuria in Thin Basement Membrane Nephropathy. <i>Seminars in Nephrology</i> , 2005, 25, 146-148.  | 0.6 | 9         |
| 201 | HMG CoA reductase inhibitors (statins) for dialysis patients. , 2009, , CD004289.  |     | 9         |
| 202 | The Affordable Dialysis Prize steams ahead. <i>Lancet, The</i> , 2016, 387, 1040.  | 6.3 | 9         |
| 203 | Renal trials in diabetes need a platform: time for a global approach?. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 356-358.  | 5.5 | 9         |
| 204 | Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2900-2911. | 3.0 | 9         |
| 205 | Association between Serum Alkaline Phosphatase and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial. <i>Canadian Journal of Kidney Health and Disease</i> , 2015, 2, 66.      | 0.6 | 8         |
| 206 | The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. <i>Redox Report</i> , 2016, 21, 14-23.                                      | 1.4 | 8         |
| 207 | Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol. <i>BMJ Open</i> , 2019, 9, e023736.   | 0.8 | 8         |
| 208 | Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis. <i>Journal of Cardiac Failure</i> , 2020, 26, 482-491.  | 0.7 | 8         |
| 209 | Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor. <i>Kidney International Reports</i> , 2021, 6, 284-295.   | 0.4 | 8         |
| 210 | Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardiovascular Assessment Study (CANVAS). <i>Diabetes Care</i> , 2022, 45, 1893-1899.  | 4.3 | 8         |
| 211 | A challenge to chronic kidney disease in Asia: The report of the second Asian Forum of Chronic Kidney Disease Initiative. <i>Nephrology</i> , 2010, 15, 248-252.   | 0.7 | 7         |
| 212 | Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study. <i>BMC Nephrology</i> , 2012, 13, 40.  | 0.8 | 7         |
| 213 | Clinical characteristics of IgA nephropathy associated with low complement 4 levels. <i>Renal Failure</i> , 2015, 37, 424-432.   | 0.8 | 7         |
| 214 | Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study. <i>BMC Nephrology</i> , 2019, 20, 258.  | 0.8 | 7         |
| 215 | Inequities in the global representation of sites participating in large, multicentre dialysis trials: a systematic review. <i>BMJ Global Health</i> , 2019, 4, e001940.  | 2.0 | 7         |
| 216 | Effect of extended hours dialysis on sleep quality in a randomized trial. <i>Nephrology</i> , 2019, 24, 430-437.   | 0.7 | 7         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 217 | The rationale and design of the <i>BLOCKER to LOWER Cardiovascular Dialysis Events (BLOCKADE) Feasibility Study</i> . <i>Nephrology</i> , 2015, 20, 140-147.  | 0.7 | 6         |
| 218 | Chronic kidney disease in Asia: Protocol for a collaborative overview. <i>Nephrology</i> , 2017, 22, 456-462.   | 0.7 | 6         |
| 219 | Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Drugs in R and D</i> , 2017, 17, 441-448.  | 1.1 | 6         |
| 220 | An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. <i>International Journal of Cardiology</i> , 2021, 324, 165-172.                      | 0.8 | 6         |
| 221 | Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 226-236.  | 1.4 | 6         |
| 222 | Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2707-2715.   | 2.2 | 6         |
| 223 | Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. <i>Diabetologia</i> , 2021, 64, 2402-2414. | 2.9 | 6         |
| 224 | New insights from ADVANCE. <i>Journal of Hypertension</i> , 2007, 25, S23-S30.  | 0.3 | 5         |
| 225 | The modifiable burden of worldwide mortality from cardiovascular diseases. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 604-606.   | 5.5 | 5         |
| 226 | Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. <i>The Cochrane Library</i> , 0, , .  | 1.5 | 5         |
| 227 | ACCORDION: Ensuring That We Hear the Music Clearly. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1621-1623.   | 2.2 | 5         |
| 228 | Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1129-1138.   | 2.2 | 5         |
| 229 | Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2199-2203.   | 2.2 | 5         |
| 230 | Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1631-1638.  | 2.3 | 5         |
| 231 | Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00247.   | 1.0 | 5         |
| 232 | The ASCEND-ND trial: study design and participant characteristics. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2157-2170.  | 0.4 | 5         |
| 233 | Is it time for Medicare change?. <i>Medical Journal of Australia</i> , 2014, 200, 566-567.  | 0.8 | 4         |
| 234 | International trials in middle-income countries: different local scenarios require different ethical approaches. <i>Journal of the Royal Society of Medicine</i> , 2016, 109, 47-51.  | 1.1 | 4         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 235 | Comparison of exposure response relationship of atrasentan between North American and Asian populations. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 545-552.  | 2.2 | 4         |
| 236 | Side effects and tolerability of combination blood pressure lowering according to blood pressure levels. <i>Journal of Hypertension</i> , 2017, 35, 1318-1325.   | 0.3 | 4         |
| 237 | Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1461-1471. | 0.4 | 4         |
| 238 | Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 498-507.  | 1.9 | 4         |
| 239 | Optimal targets for blood pressure control in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 541-546.   | 1.0 | 3         |
| 240 | Interventions for lowering plasma homocysteine levels in kidney transplant recipients. <i>The Cochrane Library</i> , 2015, 2015, CD007910.   | 1.5 | 3         |
| 241 | Knowing what we do not know: statin therapy in advanced chronic kidney disease. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 801-803.   | 5.5 | 3         |
| 242 | No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trial. <i>Nephrology</i> , 2020, 25, 792-800.   | 0.7 | 3         |
| 243 | Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis. <i>Kidney International Reports</i> , 2021, 6, 1058-1065.  | 0.4 | 3         |
| 244 | Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-12.   | 1.0 | 3         |
| 245 | How many Australian deaths from heart disease and stroke could be avoided by a small reduction in population cholesterol levels?. <i>Nutrition and Dietetics</i> , 2009, 66, 158-163.  | 0.9 | 2         |
| 246 | How to read a report of a randomized controlled trial. <i>Nephrology</i> , 2010, 15, 153-157.  | 0.7 | 2         |
| 247 | Glomerular filtration rate and the risk of stroke. <i>BMJ: British Medical Journal</i> , 2010, 341, c4390-c4390.   | 2.4 | 2         |
| 248 | Blood pressure management in diabetes: a path forward?. <i>Journal of Hypertension</i> , 2011, 29, 1283-1284.  | 0.3 | 2         |
| 249 | First Light After the Long Night: A Follow-up Report of the Randomized FHN Nocturnal Trial. <i>American Journal of Kidney Diseases</i> , 2015, 66, 379-382.  | 2.1 | 2         |
| 250 | MO051 EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .  | 0.4 | 2         |
| 251 | TO002 REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .   | 0.4 | 2         |
| 252 | PARATHYROID HORMONE HAS A PROSCLEROTIC EFFECT ON VASCULAR SMOOTH MUSCLE CELLS. <i>Nephrology</i> , 2002, 7, A69-A69.   | 0.7 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 253 | Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial. Expert Review of Endocrinology and Metabolism, 2009, 4, 111-118.   | 1.2 | 1         |
| 254 | Blood pressure in dialysis patientsâ€”look before we leap â€” Authors' reply. Lancet, The, 2009, 373, 1945-1946.  | 6.3 | 1         |
| 255 | Effects of fibrates on cardiovascular outcomes â€” Authors' reply. Lancet, The, 2010, 376, 1051-1052.   | 6.3 | 1         |
| 256 | Global Burden of Disease Study 2010: implications for nephrology. Nature Reviews Nephrology, 2013, 9, 195-197.  | 4.1 | 1         |
| 257 | Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. Nephrology Dialysis Transplantation, 2013, 28, 3127-3127. | 0.4 | 1         |
| 258 | Is it time to REWIND the cardiorenal clock in diabetes?. Lancet, The, 2019, 394, 95-97.   | 6.3 | 1         |
| 259 | Pilot Trials in Nephrology: Establishing a BASE for Large-Scale Randomized Trials. Journal of the American Society of Nephrology: JASN, 2020, 31, 4-6.  | 3.0 | 1         |
| 260 | MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS. Nephrology Dialysis Transplantation, 2021, 36, .   | 0.4 | 1         |
| 261 | LONG TERM OUTCOMES OF STENT INSERTION FOR RENAL ARTERY STENOSIS. Nephrology, 2002, 7, A7-A7.  | 0.7 | 0         |
| 262 | Prognostic value of CRP in stable coronary artery disease unclear due to a variety of biases in existing studies, therefore no clinical practice recommendations can be made. Evidence-Based Medicine, 2011, 16, 23-24.                                 | 0.6 | 0         |
| 263 | Authors' reply to Ladapo and Ogedegbe. BMJ, The, 2014, 348, g148-g148.  | 3.0 | 0         |
| 264 | Fibrates: Risk Benefits and Role in Treating Dyslipidemias. Contemporary Endocrinology, 2015, , 423-438.  | 0.3 | 0         |
| 265 | ALTITUDE: defining a ceiling for blockade of the reninâ€”angiotensin system?. Lancet Diabetes and Endocrinology,the, 2016, 4, 289-290.  | 5.5 | 0         |
| 266 | Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialistsâ€™ Collaboration. , 2018, , 433-441.  |     | 0         |
| 267 | Reducing cardiovascular risk in people with diabetes and kidney disease. Medical Journal of Australia, 2018, 209, 438-439.  | 0.8 | 0         |
| 268 | A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation. Frontiers in Cardiovascular Medicine, 2022, 9, 840611.  | 1.1 | 0         |